Aktien in diesem Artikel
Indizes in diesem Artikel
For Immediate ReleaseChicago, IL – October 7, 2021 – Zacks Director of Research Sheraz Mian says, “Total Q3 earnings for the S&P 500 index are expected to be up +26.1% from the same period last year on +13.9% higher revenues."Q3 Earnings Season Gets UnderwayNote: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>Here are the key points:We know that the earnings picture remains strong, even though the growth pace is expected to decelerate significantly from the first half’s breakneck pace. What we don’t know at this stage is whether the incremental change in the earnings outlook over the coming days, as reflected in earnings estimate revisions, will be positive or negative. Estimates for 2021 Q3, whose early reports have started coming out, have not moved up as much as had been the case in the comparable periods in the last few quarters. That said, the revisions trend remains positive and could very well gain steam as the reporting cycle gets underway. Total Q3 earnings for the S&P 500 index are expected to be up +26.1% from the same period last year on +13.9% higher revenues. This would follow the +95.0% earnings growth on +25.3% higher revenues in Q2. Rising cost pressures amid supply-chain disruptions and labor/material shortages will keep the spotlight on margins, which are expected to be up year-over-year as well as sequentially in Q3. The margins trajectory over the coming periods is a key source of uncertainty in the earnings outlook given the lack of visibility with respect to the duration of inflationary pressures. Looking at the calendar-year picture for the S&P 500 index, earnings are projected to climb +42.6% on +13.6% higher revenues in 2021 and increase +9.4% on +6.6% higher revenues in 2022. This would follow the -12.9% earnings decline on -1.7% lower revenues in 2020. For the small-cap S&P 600 index, total Q3 earnings are expected to be up +41.2% on +15.5% higher revenues, which would follow the +277.3% earnings growth on +34.4% higher revenues in 2021 Q2. The implied ‘EPS’ for the S&P 500 index, calculated using the current 2021 P/E of 22.5X and index close, as of October 5th, is $193.50, up from $135.65 in 2020. Using the same methodology, the index ‘EPS’ works out to $211.67 for 2022 (P/E of 20.5X) and $233.37 in 2023 (P/E of 18.6X). The multiples have been calculated using the index’s total market cap and aggregate bottom-up earnings for each year.The Q3 earnings season will really get underway when JPMorgan
JPM and the other major banks come out with their quarterly results next week. That’s when everyone starts paying attention to the earnings season.But the reporting cycle has actually gotten underway already, with Oracle’s ORCL September 13th release essentially kick-starting the Q3 earnings season. Including the Oracle release, we now have such Q3 results from 19 S&P 500 members including FedEx
NKE and others.All such August-period results get included with the September-quarter reports as part of the Q3 reporting cycle. We will have seen roughly two dozen such August period results by the time JPMorgan comes out with its quarterly results.Total Q3 earnings for the S&P 500 index are expected to be up +26.1% from the same period last year on +13.9% higher revenues. This would follow the +95.0% earnings growth on +25.3% higher revenues in Q2.Please note that while the Q3 estimate revisions trend remains positive, it is not as strong as we had seen in the comparable periods of the preceding two quarters. It might be nothing more than a reflection of analysts’ tentativeness about the impact of the ongoing Delta variant, but it is nevertheless something we will be closely monitoring in the days ahead.We remain positive in our earnings outlook, as we see the overall growth picture steadily improving, with the revisions trend accelerating in the days ahead.Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media ContactZacks Investment Research800-767-3771 ext. firstname.lastname@example.org://www.zacks.com Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchWeiter zum vollständigen Artikel bei "Zacks"